Achilles Historical Financial Ratios

ACHL Stock

USD 1.16 0.02 1.75%

Achilles Therapeutics is presently reporting on over 82 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.27 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Achilles Therapeutics PLC financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

About Achilles Financial Ratios Analysis

Achilles Therapeutics PLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Achilles Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Achilles financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Achilles Therapeutics history.

Achilles Therapeutics Financial Ratios Chart

At this time, Achilles Therapeutics' Income Quality is quite stable compared to the past year. Net Debt To EBITDA is expected to rise to 4.04 this year, although Book Value Per Share will most likely fall to 3.89.

Ptb Ratio Days Sales Outstanding Free Cash Flow Yield Operating Cash Flow Per Share Average Payables Graham Number

Add Fundamental

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from Achilles Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Achilles Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

	2022	2023	2024 (projected)
PB Ratio	0.18	0.25	0.29
Capex To Depreciation	2.04	0.23	0.27

Pb Ratio Capex To Depreciation

Achilles Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets
Ptb Ratio		-0.18	0.4	0.21	0.95	1.0	0.18	0.41	-0.63	0.12	0.52	-0.55	0.21	-0.18	0.02	-0.89	0.03	0.94	-0.21	0.38	-0.08	-0.97	0.39	-0.07	0.56	-0.23
Book Value Per Share	-0.18		0.5	-0.58	-0.11	-0.18	-0.57	0.28	-0.2	-0.62	0.48	-0.47	0.38	1.0	-0.35	0.26	-0.35	0.12	0.58	0.2	0.37	0.2	0.17	0.37	0.52	-0.42
Free Cash Flow Yield	0.4	0.5		0.27	0.23	0.4	0.26	0.06	-0.55	-0.79	0.82	-0.71	0.6	0.44	-0.78	-0.08	-0.78	0.56	0.7	-0.06	0.76	-0.23	-0.09	0.76	0.89	-0.56
Operating Cash Flow Per Share	0.21	-0.58	0.27		-0.07	0.21	1.0	-0.67	-0.08	-0.27	0.05	-0.14	0.02	-0.65	-0.56	0.06	-0.56	0.1	0.2	-0.69	0.54	-0.02	-0.69	0.54	-0.04	-0.01
Capex To Depreciation	0.95	-0.11	0.23	-0.07		0.95	-0.09	0.65	-0.53	0.3	0.49	-0.43	0.21	-0.09	0.26	-0.97	0.26	0.89	-0.36	0.63	-0.31	-0.99	0.64	-0.3	0.51	-0.26
Pb Ratio	1.0	-0.18	0.4	0.21	0.95		0.18	0.41	-0.63	0.12	0.52	-0.55	0.21	-0.18	0.02	-0.89	0.03	0.94	-0.21	0.38	-0.08	-0.97	0.39	-0.07	0.56	-0.23
Free Cash Flow Per Share	0.18	-0.57	0.26	1.0	-0.09	0.18		-0.69	-0.07	-0.28	0.03	-0.13	0.01	-0.64	-0.57	0.09	-0.57	0.08	0.21	-0.72	0.55	0.01	-0.71	0.55	-0.06	0.0
Roic	0.41	0.28	0.06	-0.67	0.65	0.41	-0.69		-0.15	0.36	0.43	0.0	0.36	0.34	0.51	-0.68	0.51	0.4	-0.31	0.99	-0.53	-0.57	0.99	-0.52	0.5	-0.39
Inventory Turnover	-0.63	-0.2	-0.55	-0.08	-0.53	-0.63	-0.07	-0.15		0.23	-0.47	0.77	0.19	-0.19	0.24	0.41	0.24	-0.68	-0.4	-0.1	-0.21	0.56	-0.09	-0.21	-0.6	0.14
Net Income Per Share	0.12	-0.62	-0.79	-0.27	0.3	0.12	-0.28	0.36	0.23		-0.56	0.62	-0.45	-0.55	0.95	-0.46	0.95	-0.12	-0.89	0.47	-0.96	-0.32	0.5	-0.96	-0.5	0.49
Days Of Inventory On Hand	0.52	0.48	0.82	0.05	0.49	0.52	0.03	0.43	-0.47	-0.56		-0.66	0.71	0.44	-0.52	-0.4	-0.52	0.66	0.52	0.33	0.49	-0.42	0.3	0.5	0.91	-0.89
Payables Turnover	-0.55	-0.47	-0.71	-0.14	-0.43	-0.55	-0.13	0.0	0.77	0.62	-0.66		-0.19	-0.43	0.59	0.24	0.58	-0.75	-0.55	0.09	-0.55	0.41	0.11	-0.56	-0.62	0.42
Average Inventory	0.21	0.38	0.6	0.02	0.21	0.21	0.01	0.36	0.19	-0.45	0.71	-0.19		0.35	-0.41	-0.17	-0.41	0.32	0.18	0.28	0.39	-0.15	0.26	0.4	0.63	-0.72
Cash Per Share	-0.18	1.0	0.44	-0.65	-0.09	-0.18	-0.64	0.34	-0.19	-0.55	0.44	-0.43	0.35		-0.27	0.23	-0.27	0.11	0.52	0.27	0.28	0.17	0.24	0.28	0.49	-0.38
Pocfratio	0.02	-0.35	-0.78	-0.56	0.26	0.02	-0.57	0.51	0.24	0.95	-0.52	0.59	-0.41	-0.27		-0.4	1.0	-0.16	-0.84	0.61	-1.0	-0.26	0.64	-1.0	-0.44	0.44
Capex To Operating Cash Flow	-0.89	0.26	-0.08	0.06	-0.97	-0.89	0.09	-0.68	0.41	-0.46	-0.4	0.24	-0.17	0.23	-0.4		-0.4	-0.77	0.48	-0.68	0.45	0.96	-0.69	0.44	-0.4	0.25
Pfcf Ratio	0.03	-0.35	-0.78	-0.56	0.26	0.03	-0.57	0.51	0.24	0.95	-0.52	0.58	-0.41	-0.27	1.0	-0.4		-0.16	-0.84	0.61	-1.0	-0.26	0.64	-1.0	-0.44	0.44
Days Payables Outstanding	0.94	0.12	0.56	0.1	0.89	0.94	0.08	0.4	-0.68	-0.12	0.66	-0.75	0.32	0.11	-0.16	-0.77	-0.16		-0.01	0.34	0.11	-0.89	0.34	0.12	0.67	-0.36
Income Quality	-0.21	0.58	0.7	0.2	-0.36	-0.21	0.21	-0.31	-0.4	-0.89	0.52	-0.55	0.18	0.52	-0.84	0.48	-0.84	-0.01		-0.41	0.85	0.38	-0.44	0.85	0.48	-0.47
Roe	0.38	0.2	-0.06	-0.69	0.63	0.38	-0.72	0.99	-0.1	0.47	0.33	0.09	0.28	0.27	0.61	-0.68	0.61	0.34	-0.41		-0.63	-0.55	1.0	-0.62	0.39	-0.3
Ev To Operating Cash Flow	-0.08	0.37	0.76	0.54	-0.31	-0.08	0.55	-0.53	-0.21	-0.96	0.49	-0.55	0.39	0.28	-1.0	0.45	-1.0	0.11	0.85	-0.63		0.31	-0.66	1.0	0.41	-0.43
Pe Ratio	-0.97	0.2	-0.23	-0.02	-0.99	-0.97	0.01	-0.57	0.56	-0.32	-0.42	0.41	-0.15	0.17	-0.26	0.96	-0.26	-0.89	0.38	-0.55	0.31		-0.57	0.3	-0.47	0.16
Return On Tangible Assets	0.39	0.17	-0.09	-0.69	0.64	0.39	-0.71	0.99	-0.09	0.5	0.3	0.11	0.26	0.24	0.64	-0.69	0.64	0.34	-0.44	1.0	-0.66	-0.57		-0.65	0.36	-0.27
Ev To Free Cash Flow	-0.07	0.37	0.76	0.54	-0.3	-0.07	0.55	-0.52	-0.21	-0.96	0.5	-0.56	0.4	0.28	-1.0	0.44	-1.0	0.12	0.85	-0.62	1.0	0.3	-0.65		0.42	-0.43
Earnings Yield	0.56	0.52	0.89	-0.04	0.51	0.56	-0.06	0.5	-0.6	-0.5	0.91	-0.62	0.63	0.49	-0.44	-0.4	-0.44	0.67	0.48	0.39	0.41	-0.47	0.36	0.42		-0.66
Intangibles To Total Assets	-0.23	-0.42	-0.56	-0.01	-0.26	-0.23	0.0	-0.39	0.14	0.49	-0.89	0.42	-0.72	-0.38	0.44	0.25	0.44	-0.36	-0.47	-0.3	-0.43	0.16	-0.27	-0.43	-0.66

Click cells to compare fundamentals

Achilles Therapeutics Account Relationship Matchups

Achilles Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	0.27	3.55	0.5	0.18	0.25	0.29
Book Value Per Share	4.66	10.1	5.03	3.56	4.1	3.89
Free Cash Flow Yield	(0.0552)	(0.47)	(1.9)	(1.39)	(1.6)	(1.68)
Operating Cash Flow Per Share	(0.62)	(2.07)	(1.52)	(1.21)	(1.09)	(1.15)
Capex To Depreciation	15.35	2.32	2.04	0.23	0.27	0.25
Pb Ratio	0.27	3.55	0.5	0.18	0.25	0.29
Free Cash Flow Per Share	(0.91)	(2.34)	(1.71)	(1.24)	(1.12)	(1.17)
Roic	(0.18)	(0.22)	(0.4)	(0.53)	(0.61)	(0.64)
Net Income Per Share	(0.82)	(2.13)	(1.82)	(1.74)	(1.57)	(1.65)
Days Of Inventory On Hand	824.76	569.88	457.67	7.7E-5	8.9E-5	8.4E-5
Payables Turnover	0.12	0.88	0.71	0.84	0.76	0.46
Cash Per Share	4.38	9.29	4.43	3.29	3.78	3.6
Pocfratio	(26.62)	(2.42)	(0.59)	(0.73)	(0.66)	(0.69)
Capex To Operating Cash Flow	(0.0666)	(0.47)	(0.13)	(0.0227)	(0.0204)	(0.0215)
Pfcf Ratio	(18.12)	(2.15)	(0.53)	(0.72)	(0.65)	(0.68)
Days Payables Outstanding	3.0K	413.23	513.39	434.26	499.4	474.43
Income Quality	0.76	0.97	0.84	0.69	0.8	0.99
Roe	(0.18)	(0.21)	(0.36)	(0.49)	(0.56)	(0.59)
Ev To Operating Cash Flow	(20.21)	1.86	2.18	1.89	2.17	2.06
Pe Ratio	(20.25)	(2.35)	(0.49)	(0.51)	(0.46)	(0.48)
Return On Tangible Assets	(0.15)	(0.19)	(0.32)	(0.43)	(0.5)	(0.52)
Ev To Free Cash Flow	(13.76)	1.65	1.93	1.84	2.12	2.02
Earnings Yield	(0.0494)	(0.43)	(2.02)	(1.96)	(2.25)	(2.14)
Net Debt To E B I T D A	4.91	4.4	2.1	1.8	2.07	4.04
Current Ratio	11.3	14.9	10.93	8.57	9.85	15.18
Tangible Book Value Per Share	4.66	10.11	5.04	3.56	4.1	3.89
Graham Number	9.26	22.02	14.35	11.82	13.59	12.91
Shareholders Equity Per Share	4.66	10.1	5.03	3.56	4.1	3.89
Capex Per Share	0.29	0.27	0.19	0.0275	0.0316	0.0301
Graham Net Net	3.81	8.71	4.2	3.01	3.46	3.29
Enterprise Value Over E B I T D A	(15.49)	1.91	1.65	1.3	1.17	1.23
Price Earnings Ratio	(20.25)	(2.35)	(0.49)	(0.51)	(0.46)	(0.48)
Operating Cycle	824.76	569.88	457.67	7.7E-5	8.9E-5	8.4E-5
Price Book Value Ratio	0.27	3.55	0.5	0.18	0.25	0.29
Price Earnings To Growth Ratio	0.22	(0.0147)	0.034	0.12	0.13	0.0921
Days Of Payables Outstanding	3.0K	413.23	513.39	434.26	499.4	474.43
Price To Operating Cash Flows Ratio	(26.62)	(2.42)	(0.59)	(0.73)	(0.66)	(0.69)
Price To Free Cash Flows Ratio	(18.12)	(2.15)	(0.53)	(0.72)	(0.65)	(0.68)
Ebt Per Ebit	1.02	0.98	0.95	0.91	0.92	1.06

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:

How To Invest In Achilles

Details

Is Achilles Stock a good investment?

Details

What is Achilles Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.66)

Return On Assets

(0.27)

Return On Equity

(0.44)

The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Achilles Historical Financial Ratios

About Achilles Financial Ratios Analysis

Achilles Therapeutics Financial Ratios Chart

Ptb Ratio

Free Cash Flow Yield

Operating Cash Flow Per Share

Average Payables

Achilles Therapeutics fundamentals Correlations

Achilles Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Achilles Therapeutics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Return On Tangible Assets	+ 1.0	Roe
Ev To Free Cash Flow	+ 1.0	Ev To Operating Cash Flow

Ev To Free Cash Flow	- 1.0	Pfcf Ratio
Ev To Operating Cash Flow	- 1.0	Pfcf Ratio
Ev To Free Cash Flow	- 1.0	Pocfratio
Ev To Operating Cash Flow	- 1.0	Pocfratio
Pe Ratio	- 0.99	Capex To Depreciation
Pe Ratio	- 0.97	Pb Ratio